Search

Your search keyword '"Signoriello, Giuseppe"' showing total 525 results
Start Over Author "Signoriello, Giuseppe"
525 results on '"Signoriello, Giuseppe"'

56. Second Diagnostic Opinion by Experienced Dermatopathologists in the Setting of a Referral Regional Melanoma Unit Significantly Improves the Clinical Management of Patients With Cutaneous Melanoma

Author

Ronchi, Andrea, primary, Pagliuca, Francesca, additional, Zito Marino, Federica, additional, Argenziano, Giuseppe, additional, Brancaccio, Gabriella, additional, Alfano, Roberto, additional, Signoriello, Giuseppe, additional, Moscarella, Elvira, additional, and Franco, Renato, additional

Published
2021
Full Text
View/download PDF

57. Diagnostic performance of melanocytic markers for immunocytochemical evaluation of lymph-node melanoma metastases on cytological samples

Author

Ronchi, Andrea, primary, Zito Marino, Federica, additional, Toni, Giorgio, additional, Pagliuca, Francesca, additional, Russo, Daniela, additional, Signoriello, Giuseppe, additional, Moscarella, Elvira, additional, Brancaccio, Gabriella, additional, Argenziano, Giuseppe, additional, Franco, Renato, additional, and Cozzolino, Immacolata, additional

Published
2021
Full Text
View/download PDF

60. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

Author

Cardone, Claudia, primary, Blauensteiner, Bernadette, additional, Moreno-Viedma, Veronica, additional, Martini, Giulia, additional, Simeon, Vittorio, additional, Vitiello, Pietro P., additional, Ciardiello, Davide, additional, Belli, Valentina, additional, Matrone, Nunzia, additional, Troiani, Teresa, additional, Morgillo, Floriana, additional, Zito Marino, Federica, additional, Dentice, Monica, additional, Nappi, Annarita, additional, Boccaccino, Alessandra, additional, Antoniotti, Carlotta, additional, Cremolini, Chiara, additional, Pietrantonio, Filippo, additional, Prager, Gerald W., additional, Normanno, Nicola, additional, Maiello, Evaristo, additional, Argiles, Guillem, additional, Elez, Elena, additional, Signoriello, Giuseppe, additional, Franco, Renato, additional, Falcone, Alfredo, additional, Tabernero, Josep, additional, Sibilia, Maria, additional, Ciardiello, Fortunato, additional, and Martinelli, Erika, additional

Published
2020
Full Text
View/download PDF

62. Diagnostic performance of melanocytic markers for immunocytochemical evaluation of lymph-node melanoma metastases on cytological samples.

Author

Ronchi, Andrea, Marino, Federica Zito, Toni, Giorgio, Pagliuca, Francesca, Russo, Daniela, Signoriello, Giuseppe, Moscarella, Elvira, Brancaccio, Gabriella, Argenziano, Giuseppe, Franco, Renato, and Cozzolino, Immacolata

Subjects
METASTASIS, SENTINEL lymph nodes, MELANOMA, MEDICAL sciences, ANDROGEN receptors, EXUDATES & transudates
Published
2022
Full Text
View/download PDF

68. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018)

Author

Sardu Celestino, Barbieri Michelangela, Balestrieri Maria Luisa, Siniscalchi Mario, Paolisso Pasquale, Calabrò Paolo, Minicucci Fabio, Signoriello Giuseppe, Portoghese Michele, Mone Pasquale, D'Andrea Davide, Gragnano Felice, Bellis Aelssandro, Mauro Ciro, Paolisso Giuseppe, Rizzo Maria Rosaria, Marfella Raffaele, Sardu, Celestino, Barbieri, Michelangela, Balestrieri, Maria Luisa, Siniscalchi, Mario, Paolisso, Pasquale, Calabrò, Paolo, Minicucci, Fabio, Signoriello, Giuseppe, Portoghese, Michele, Mone, Pasquale, D'Andrea, Davide, Gragnano, Felice, Bellis, Aelssandro, Mauro, Ciro, Paolisso, Giuseppe, Rizzo, Maria Rosaria, and Marfella, Raffaele

Abstract

Following publication of the original article [1], the authors reported an error in Acknowledgment section. The last sentence should read as All authors have read and approval the submission to Cardiovascular Diabetology.

Published
2018

75. Network Italiano Asplenia: dati allarmanti sullo stato di copertura vaccinale nei pazienti asplenici registrati

Author

Casale, Maddalena, Forni Gian Luca, Signoriello, Giuseppe, Masera, Nicoletta, Corti, Paola, Cesaro, Simone, Giona, Fiorina, Saracco, Paola, Graziadei, Giovanna, Barella, Susanna, Zecca, Marco, Colombatti, Raffaella, Ladogana, Saverio, Baronci, Carlo, Pellegrina, Pugliese, and Notarangelo Lucia Dora

Subjects
asplenia, infezioni, vaccinazioni, vaccinazioni, asplenia, infezioni
Published
2018

76. HBV vaccination status among healthcare workers: A cross-sectional study

Author

Garzillo, Elpidio Maria, primary, Arnese, Antonio, additional, Coppola, Nicola, additional, Corvino, AnnaRita, additional, Feola, Daniela, additional, Monaco, Maria Grazia Lourdes, additional, Signoriello, Giuseppe, additional, Marsella, Luigi Tonino, additional, Arena, Paola, additional, and Lamberti, Monica, additional

Published
2019
Full Text
View/download PDF

79. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, additional, Vitiello, Pietro Paolo, additional, Belli, Valentina, additional, Napolitano, Stefania, additional, Troiani, Teresa, additional, Ciardiello, Davide, additional, Della Corte, Carminia Maria, additional, Morgillo, Floriana, additional, Matrone, Nunzia, additional, Sforza, Vincenzo, additional, Papaccio, Gianpaolo, additional, Desiderio, Vincenzo, additional, Paul, Mariel C., additional, Moreno-Viedma, Veronica, additional, Normanno, Nicola, additional, Rachiglio, Anna Maria, additional, Tirino, Virginia, additional, Maiello, Evaristo, additional, Latiano, Tiziana Pia, additional, Rizzi, Daniele, additional, Signoriello, Giuseppe, additional, Sibilia, Maria, additional, Ciardiello, Fortunato, additional, and Martinelli, Erika, additional

Published
2019
Full Text
View/download PDF

81. Long‐term improvement in cardiac magnetic resonance in β‐thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function

Author

Casale, Maddalena, primary, Filosa, Aldo, additional, Ragozzino, Alfonso, additional, Amendola, Giovanni, additional, Roberti, Domenico, additional, Tartaglione, Immacolata, additional, De Michele, Elisa, additional, Cozzolino, Domenico, additional, Rispoli, Giuliana, additional, Palmieri, Francesco, additional, Pugliese, Umberto, additional, Scianguetta, Saverio, additional, Signoriello, Giuseppe, additional, Musallam, Khaled M., additional, and Perrotta, Silverio, additional

Published
2018
Full Text
View/download PDF

83. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

Author

Staiano Maria, La Vecchia Franca, Formichelli Franca, Curcio Maria, Di Bonito Maurizio, Botti Gerardo, Silvestro Pasqualina, Rossi Emanuela, Nuzzo Francesco, Landi Gabriella, Labonia Vincenzo, Di Rella Francesca, Morabito Alessandro, Gravina Adriano, Pacilio Carmen, De Maio Ermelinda, Maurea Nicola, D'Aiuto Giuseppe, D'Aiuto Massimiliano, Thomas Renato, Signoriello Giuseppe, Perrone Francesco, and de Matteis Andrea

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background After two studies reporting response rates higher than 70% in HER2-positive metastatic breast cancer with weekly trastuzumab and vinorelbine, we planned a phase 2 study to test activity of the same combination, with trastuzumab given every 3 weeks. Methods Patients with HER2-positive metastatic breast cancer (3+ at immunohistochemistry or positive at fluorescence in situ hybridization), PS ≤2, normal left-ventricular ejection fraction (LVEF) and no more than one chemotherapy line for metastatic disease were eligible. Vinorelbine (30 mg/m2) was given on days 1&8 every 21 and trastuzumab (8 mg/kg day 1, then 6 mg/kg) every 21 days). A single-stage phase 2 design, with p0 = 0.45, p1 = 0.65, type I and II error = 0.10, was applied; 22 objective responses were required in 39 patients. Results From Nov 2002 to May 2005, 50 patients were enrolled, with a median age of 54 years (range 31–81). Among 40 patients eligible for response assessment, there were 7 complete and 13 partial responses (overall response rate 50%; 95% exact CI 33.8–66.2); 11 patients had disease stabilization, lasting more than 6 months in 10 cases. Response rate did not vary according to patients and tumor characteristics, type and amount of previous chemotherapy. Within the whole series, median progression-free survival was 9.6 months (95% CI 7.3–12.3), median overall survival 22.7 months (95% CI 19.5-NA). Fifteen patients (30%) developed brain metastases at a median time of 12 months (range 1–25). There was one toxic death due to renal failure in a patient receiving concomitant pamidronate. Twenty-three patients (46%) had grade 3–4 neutropenia, 2 (4%) grade 3 anemia, 4 (8%) febrile neutropenia. Two patients stopped treatment because of grade 2 decline of LVEF and one patient because of grade 2 liver toxicity concomitant with a grade 1 decline of LVEF. One patient stopped trastuzumab after 50 cycles because of grade 1 decline of LVEF. Conclusion Although lower than in initial studies, activity of 3-weekly trastuzumab plus vinorelbine fell within the range of results reported with weekly schedules. Toxicity was prevalently manageable. This combination is safe and active for metastatic breast cancer patients who received adjuvant taxanes with anthracyclines.

Published
2007
Full Text
View/download PDF

84. Coronary artery bifurcation narrowing treated by Axxess stent implantation: The CARINAX registry

Author

Briguori, Carlo, Donahue, MICHAEL EDWARD, Visconti, Gabriella, Focaccio, Amelia, Pennacchi, Mauro, Lucisano, Luigi, Stio, ROCCO EDOARDO, Mancone, Massimo, Calcagno, Simone, Di Palma, Vito, Labalestra, Nicola, Signoriello, Giuseppe, Sardella, Gennaro, Briguori, Carlo, Donahue, Michael, Visconti, Gabriella, Focaccio, Amelia, Pennacchi, Mauro, Lucisano, Luigi, Stio, Rocco, Mancone, Massimo, Calcagno, Simone, Di Palma, Vito, Labalestra, Nicola, Signoriello, Giuseppe, and Sardella, Gennaro

Subjects
Male, Sirolimus, coronary bifurcation lesion, percutaneous coronary intervention, Coronary Stenosis, Drug-Eluting Stents, Coronary Angiography, Prosthesis Design, Coronary Vessels, Coronary bifurcation lesions, coronary self-expanding drug-eluting stent, cardiology and cardiovascular medicine, radiology, nuclear medicine and imaging, Humans, Female, Prospective Studies, Registries, Propensity Score, Immunosuppressive Agents, Ultrasonography, Interventional, Aged, Follow-Up Studies
Abstract

To compare the safety and efficacy of the Axxess™ biolimus-eluting stent with the second-generation drug-eluting stent (DES) in the treatment of bifurcation lesions.The Axxess™ is a dedicated bifurcation stent, designed to cover the lesion at the carina level.Between April 2012 and August 2014, 165 patients with de novo bifurcation lesions were treated with the Axxess™ stent (Axxess group). A propensity-score matched group of 165 patients treated with DES in the same period was selected (Control group). The primary objectives were (1) the procedural complication rate, including side branch (SB) occlusion and trouble in SB access after main vessel stenting; and (2) the device, the angiographic, and the procedural success rate.Procedural complications occurred in 1 patient (0.6%) in the Axxess group and in 20 patients (12%) in the Control group (OR = 0.03; 95% confidence interval 0.005-0.27; P 0.001). Device success was obtained in 164 (99.5%) patients in the Axxess group and in all in the Control group (P = 1.00). Angiographic success was obtained in all patients. Inaccurate Axxess™ stent position occurred in 21 (13%) patients, and was more often associated with moderate-to-severe calcifications and distal lesion site. Procedural success was obtained in 91.5% patients in the Axxess group and in 90% patients in the Control group (P = 0.72).The present registry suggests that the Axxess™ stent (1) may represent a valid alternative approach for the treatment of bifurcation lesions and (2) should be avoided in moderate-to-severe calcifications and/or in distal lesions. © 2016 Wiley Periodicals, Inc.

Published
2016

85. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Author

D'Arco Alfonso, Musso Pietro, Ferro Antonella, Naglieri Emanuele, Del Gaizo Filomena, Natale Donato, Gebbia Vittorio, Rossi Emanuela, De Vivo Rocco, Scollo Paolo, Breda Enrico, Savarese Antonella, Scambia Giovanni, Pignata Sandro, Sorio Roberto, Pisano Carmela, Di Maio Massimo, Signoriello Giuseppe, Annunziata Annalisa, and Perrone Francesco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged < 75 years, ECOG performance status ≤ 2, were randomized to carboplatin AUC 5 plus paclitaxel 175 mg/m2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed in July 2004. Data from the first 50 patients treated with carboplatin plus pegylated liposomal doxorubicin were evaluated. Median age was 60 years (range 34–75). Forty-three patients (86%) completed 6 cycles. Two thirds of the patients had at least one cycle delayed due to toxicity, but 63% of the cycles were administered on time. In most cases the reason for chemotherapy delay was neutropenia or other hematological toxicity. No delay due to palmar-plantar erythrodysesthesia (PPE) was recorded. No toxic death was recorded. Reported hematological toxicities were: grade (G) 3 anemia 16%, G3/G4 neutropenia 36% and 10% respectively, G3/4 thrombocytopenia 22% and 4% respectively. Non-haematological toxicity was infrequent: pulmonary G1 6%, heart rhythm G1 4%, liver toxicity G1 6%, G2 4% and G3 2%. Complete hair loss was reported in 6% of patients, and G1 neuropathy in 2%. PPE was recorded in 14% of the cases (G1 10%, G2 2%, G3 2%). Conclusion This safety analysis shows that the adopted schedule of carboplatin plus pegylated liposomal doxorubicin given every 3 weeks is feasible as first line treatment in ovarian cancer patients, although 37% of the cycles were delayed due to haematological toxicity. Toxicities that are common with standard combination of carboplatin plus paclitaxel (neurotoxicity and hair loss) are infrequent with this experimental schedule, and skin toxicity appears manageable.

Published
2006
Full Text
View/download PDF

86. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

Author

Daniele Bruno, Signoriello Giuseppe, Di Maio Massimo, De Maio Ermelinda, Gallo Ciro, Pignata Sandro, Annunziata Annalisa, and Perrone Francesco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Large randomised clinical trials and systematic reviews substantiate that tamoxifen is ineffective in improving survival of patients with hepatocellular carcinoma (HCC). However, a recent report suggested that the drug might prolong survival among patients with well preserved liver function. The aim of this paper is to validate this hypothesis. Methods We used the updated database of the phase 3 randomised CLIP-1 trial that compared tamoxifen with supportive therapy. Primary endpoint was overall survival. Treatment arms were compared within strata defined according to the Okuda stage and the CLIP-score. Survival differences were tested by the Log-rank test. Results Tamoxifen was not effective in prolonging survival in Okuda I-II subgroup (p = 0.501). Median survival times were equal to 16.8 (95%CI 12.7–18.5) months for tamoxifen and 16.8 (95%CI 13.5–22.4) months for the control arms; 1-year survival probabilities were equal to 58.8% (95%CI 51.7–65.8) and 59.4 (95%CI 52.5–66.2), respectively. Similar results were observed in the better CLIP subgroup (score 0/1), without evidence of difference between the two treatment arms (p = 0.734). Median survival times were equal to 29.2 (95%CI 20.1–36.4) months with tamoxifen and 29.0 (95%CI 23.3–35.2) months without; 1-year survival probabilities were equal to 80.9% (95%CI 72.5–89.3) with tamoxifen and 77.1% (95%CI 68.6–85.7) for the control arm. Conclusion The recent suggestion that tamoxifen might be effective in the subgroup of patients with better prognosis is not supported by a reanalysis of the CLIP-1 trial. Tamoxifen should no longer be considered for the treatment of HCC patients and future trials of medical treatment should concentrate on different drugs.

Published
2006
Full Text
View/download PDF

87. Long-Term Bowel Function and Fate of the Ileal Pouch After Restorative Proctocolectomy in Patients With Crohn's Disease: A Systematic Review With Meta-Analysis and Metaregression.

Author

Pellino, Gianluca, Vinci, Danilo, Signoriello, Giuseppe, Kontovounisios, Christos, Canonico, Silvestro, Selvaggi, Francesco, and Sciaudone, Guido

Abstract

Background and Aims Debate exists on whether ileal pouch anal anastomosis [IPAA] can be safely offered to patients diagnosed with Crohn's disease [CD]. Our aim was to assess the outcome of IPAA for CD vs ulcerative colitis [UC]. Methods We used a PRISMA/MOOSE-compliant meta-analysis. Studies published between 1993 and 2018 were retrieved. Primary end points included complications. Secondary endpoints included functional outcome. The time of CD diagnosis was considered [intentional vs incidental IPAA]. Results Eleven studies comprising 6770 patients [CD = 352, UC = 6418] were included, with 44–120 months of follow-up. Pouch fistulae were more common in CD (CD vs UC; odds ratio (OR) 6.08; p = 0.0003, GRADE+++), as were strictures [OR 1.82; p = 0.02, GRADE+++] and failure [OR 5.27; p < 0.0001, GRADE++++]. Compared with UC, postoperative CD diagnosis was associated with a much higher risk of fistulae [OR 6.23; p = 0.006, GRADE+++] and failure [OR 8.53; p < 0.0001, GRADE++++] than intentional IPAA in CD [fistula: OR 4.17; p = 0.04, GRADE+++; failure: OR 2.48; p = 0.009, GRADE++++]. Age at surgery was positively associated with failure in CD [ p = 0.007]. Obstruction was more common after intentional IPAA for CD. The risk of pouchitis did not differ between CD and UC [OR 1.07, p = 0.76, GRADE+++]. CD patients were at a higher risk of seepage [OR 2.27; p = 0.010, GRADE++]. Conclusions Patients with CD have 5-fold higher risk of failure, and a 2-fold risk of strictures after IPAA compared with UC. The risk is much higher if diagnosis is performed after IPAA. Function in those who retain the pouch seemed similar to that of patients with UC. CD does not increase the risk of pouchitis. IPAA could be offered to a selected population of CD patients after proper preoperative counselling. [PROSPERO registry 116811] [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

88. HBV vaccination status among healthcare workers: A cross-sectional study.

Author

Garzillo, Elpidio Maria, Arnese, Antonio, Coppola, Nicola, Corvino, AnnaRita, Feola, Daniela, Monaco, Maria Grazia Lourdes, Signoriello, Giuseppe, Marsella, Luigi Tonino, Arena, Paola, and Lamberti, Monica

Subjects
HEPATITIS B, HEPATITIS B vaccines, MULTIVARIATE analysis, CROSS-sectional method, DESCRIPTIVE statistics
Abstract

Objective: The development of a vaccine against hepatitis B virus (HBV) is one of the improvements in strategy prevention during the last decades. Aim: To evaluate HBV-related vaccine status in healthcare workers (HCW) exposed to biological risk. Methods: The serum markers for HBV were collected from HCWs in two tertiary care hospitals in Naples (Italy). Multivariate statistical analysis was then performed to identify associated factors linked to the long-term immunogenicity of the HCWs. Results: All HBV vaccinated individuals were screened for whole marker patterns; all were HBsAg/anti-HBc negative. Of individuals, 20% had an anti-HB antibody titre < 10 IU/L. Multivariate statistical analysis highlighted that women were more protected than men (73.6% vs. 26.4%, P < 0.05). Additionally, nurses seem to maintain a higher antibody titre than doctors and other staff, such as auxiliary technicians (P < 0.05). Conclusions: Our data support the evidence of a strong immunogenicity against HBV, assessed through the circulating antibody titre, when prophylactic vaccination is conducted in non-infantile age, particularly for women. The outcome of the study supports the central role of occupational physicians within the hospital districts in terms of primary prevention and maximum protection of HCWs. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

89. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Author

De Placido, Sabino, primary, Gallo, Ciro, additional, De Laurentiis, Michelino, additional, Bisagni, Giancarlo, additional, Arpino, Grazia, additional, Sarobba, Maria Giuseppa, additional, Riccardi, Ferdinando, additional, Russo, Antonio, additional, Del Mastro, Lucia, additional, Cogoni, Alessio Aligi, additional, Cognetti, Francesco, additional, Gori, Stefania, additional, Foglietta, Jennifer, additional, Frassoldati, Antonio, additional, Amoroso, Domenico, additional, Laudadio, Lucio, additional, Moscetti, Luca, additional, Montemurro, Filippo, additional, Verusio, Claudio, additional, Bernardo, Antonio, additional, Lorusso, Vito, additional, Gravina, Adriano, additional, Moretti, Gabriella, additional, Lauria, Rossella, additional, Lai, Antonella, additional, Mocerino, Carmela, additional, Rizzo, Sergio, additional, Nuzzo, Francesco, additional, Carlini, Paolo, additional, Perrone, Francesco, additional, Accurso, Antonello, additional, Agostara, Biagio, additional, Aieta, Michele, additional, Alabiso, Oscar, additional, Alicicco, Maria Grazia, additional, Amadori, Dino, additional, Amaducci, Laura, additional, Amiconi, Gianna, additional, Antuzzi, Giustino, additional, Ardine, Mara, additional, Ardizzoia, Antonio, additional, Aversa, Caterina, additional, Badalamenti, Giuseppe, additional, Barni, Sandro, additional, Basurto, Carlo, additional, Berardi, Rossana, additional, Bergamasco, Cinzia, additional, Bidoli, Paolo, additional, Bighin, Claudia, additional, Biondi, Edoardo, additional, Boni, Corrado, additional, Borgonovo, Karen, additional, Botta, Mario, additional, Bravi, Stefano, additional, Bruzzi, Paolo, additional, Buono, Giuseppe, additional, Butera, Alfredo, additional, Caldara, Alessia, additional, Candeloro, Giampiero, additional, Cappelletti, Claudia, additional, Cardalesi, Cinzia, additional, Carfora, Elisabetta, additional, Cariello, Anna, additional, Carrozza, Francesco, additional, Cartenì, Giacomo, additional, Caruso, Michele, additional, Casadei, Virginia, additional, Casanova, Claudia, additional, Castori, Luigi, additional, Cavanna, Luigi, additional, Cavazzini, Giovanna, additional, Cazzaniga, Marina, additional, Chilelli, Mario, additional, Chiodini, Paolo, additional, Chiorrini, Silvia, additional, Ciardiello, Fortunato, additional, Ciccarese, Mariangela, additional, Cinieri, Saverio, additional, Clerico, Mario, additional, Coccaro, Mariarosa, additional, Comande, Mario, additional, Corbo, Claudia, additional, Cortino, Giuseppina, additional, Cusenza, Stefania, additional, Daniele, Gennaro, additional, D'arco, Alfonso Maria, additional, D'auria, Giuliana, additional, Dazzi, Claudio, additional, De Angelis, Carmine, additional, de Braud, Filippo, additional, De Feo, Gianfranco, additional, De Matteis, Andrea, additional, De Tursi, Michele, additional, Di Blasio, Anna, additional, di Lucca, Giuseppe, additional, Di Lullo, Liberato, additional, Di Rella, Francesca, additional, Di Renzo, Gianfranco, additional, Di Stefano, Pia, additional, Di Stefano, Aida, additional, Diana, Anna, additional, Donati, Sara, additional, Fabbri, Agnese, additional, Fabi, Alessandra, additional, Faedi, Marina, additional, Farina, Gabriella, additional, Farris, Antonio, additional, Febbraro, Antonio, additional, Fedele, Palma, additional, Federico, Piera, additional, Ferraù, Francesco, additional, Ferretti, Gianluigi, additional, Ferro, Antonella, additional, Floriani, Irene, additional, Forcignanò, Rosachiara, additional, Forciniti, Samantha, additional, Forestieri, Valeria, additional, Fornari, Gianni, additional, Frisinghelli, Michela, additional, Fusco, Vittorio, additional, Gallizzi, Giulia, additional, Galvano, Antonio, additional, Gambardella, Antonio, additional, Gambi, Angelo, additional, Gebbia, Vittorio, additional, Gervasi, Erika, additional, Ghilardi, Mara, additional, Giacobino, Alice, additional, Giardina, Giovanni, additional, Giotta, Francesco, additional, Giraudi, Sara, additional, Giuliano, Mario, additional, Grassadonia, Antonino, additional, Grasso, Donatella, additional, Grosso, Federica, additional, Guizzaro, Lorenzo, additional, Incoronato, Pasquale, additional, Incorvaia, Lorena, additional, Iodice, Giovanni, additional, La Verde, Nicla, additional, Labonia, Vincenzo, additional, Landi, Gabriella, additional, Latorre, Agnese, additional, Leonardi, Vita, additional, Levaggi, Alessia, additional, Limite, Gennaro, additional, Lina Bascialla, Linda, additional, Livi, Lorenzo, additional, Maiello, Evaristo, additional, Mandelli, Daniela, additional, Marcon, Ilaria, additional, Menon, Daniela, additional, Montedoro, Michele, additional, Moraca, Lucia, additional, Moretti, Anna, additional, Morritti, Maria Grazia, additional, Morselli, Patrizia, additional, Mura, Antonella, additional, Mura, Silvia, additional, Musacchio, Michela, additional, Muzio, Alberto, additional, Natale, Donato, additional, Natoli, Clara, additional, Nigro, Cinzia, additional, Nisticò, Cecilia, additional, Nuzzo, Antonio, additional, Orditura, Michele, additional, Orlando, Laura, additional, Pacilio, Carmen, additional, Palumbo, Giuliano, additional, Palumbo, Raffaella, additional, Pasini, Felice, additional, Paterno, Emanuela, additional, Pazzola, Antonio, additional, Pelliccioni, Silvia, additional, Pensabene, Matilde, additional, Perroni, Davide, additional, Pesenti Gritti, Angela, additional, Petrelli, Fausto, additional, Piccirillo, Maria Carmela, additional, Pinotti, Graziella, additional, Pogliani, Claudia, additional, Poli, Davide, additional, Prader, Sonia, additional, Recchia, Francesco, additional, Rizzi, Daniele, additional, Romano, Carmen, additional, Rossello, Rosalba, additional, Rossini, Chiara, additional, Salvucci, Giuseppina, additional, Sanna, Valeria, additional, Santini, Alessandra, additional, Saracchini, Silvana, additional, Savastano, Clementina, additional, Scambia, Giovanni, additional, Schettini, Francesco, additional, Schiavone, Paola, additional, Schirone, Alessio, additional, Seles, Elena, additional, Signoriello, Simona, additional, Signoriello, Giuseppe, additional, Silva, Rosa Rita, additional, Silvestri, Antonia, additional, Simeon, Vittorio, additional, Spagnoletti, Ilaria, additional, Tamberi, Stefano, additional, Teragni, Cristina, additional, Thalmann, Verena, additional, Thomas, Renato, additional, Thomas, Guglielmo, additional, Tienghi, Amelia, additional, Tinari, Nicola, additional, Tinessa, Vincenza, additional, Tomei, Federica, additional, Tonini, Giuseppe, additional, Torri, Valter, additional, Traficante, Divina, additional, Tudini, Marianna, additional, Turazza, Monica, additional, Vignoli, Roberto, additional, Vitale, Maria Giuseppa, additional, Zacchia, Alessandra, additional, Zagarese, Pasquale, additional, Zanni, Alda, additional, Zavallone, Laura, additional, Zavettieri, Maria, additional, and Zoboli, Alessandra, additional

Published
2018
Full Text
View/download PDF

90. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis

Author

Marfella, Raffaele, primary, Sardu, Celestino, additional, Balestrieri, Maria Luisa, additional, Siniscalchi, Mario, additional, Minicucci, Fabio, additional, Signoriello, Giuseppe, additional, Calabrò, Paolo, additional, Mauro, Ciro, additional, Pieretti, Gorizio, additional, Coppola, Antonino, additional, Nicoletti, Gianfranco, additional, Rizzo, Maria Rosaria, additional, Paolisso, Giuseppe, additional, and Barbieri, Michelangela, additional

Published
2018
Full Text
View/download PDF

91. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment

Author

Marfella, Raffaele, primary, Sardu, Celestino, additional, Calabrò, Paolo, additional, Siniscalchi, Mario, additional, Minicucci, Fabio, additional, Signoriello, Giuseppe, additional, Balestrieri, Maria L., additional, Mauro, Ciro, additional, Rizzo, Maria R., additional, Paolisso, Giuseppe, additional, and Barbieri, Michelangela, additional

Published
2017
Full Text
View/download PDF

92. Additional file 1: Table S1. of Prevalence of latent tuberculosis infection in healthcare workers at a hospital in Naples, Italy, a low-incidence country

Author

Lamberti, Monica, Mariarosaria Muoio, Arnese, Antonio, Borrelli, Sharon, Lorenzo, Teresa Di, Garzillo, Elpidio, Signoriello, Giuseppe, Pascalis, Stefania De, Coppola, Nicola, and Nienhaus, Albert

Subjects
bacterial infections and mycoses
Abstract

Demographic, epidemiological and clinical characteristics of the hospital personnel completing the study stratified for latent TB infection, as diagnosed in all participants found positive at TST. (DOC 41 kb)

Published
2016
Full Text
View/download PDF

93. Additional file 2: Table S2. of Prevalence of latent tuberculosis infection in healthcare workers at a hospital in Naples, Italy, a low-incidence country

Author

Lamberti, Monica, Mariarosaria Muoio, Arnese, Antonio, Borrelli, Sharon, Lorenzo, Teresa Di, Garzillo, Elpidio, Signoriello, Giuseppe, Pascalis, Stefania De, Coppola, Nicola, and Nienhaus, Albert

Subjects
mental disorders, bacterial infections and mycoses, humanities
Abstract

Logistic regression analysis for independent predictors of LTBI, as diagnosed in all participants found positive at TST. (DOCX 17 kb)

Published
2016
Full Text
View/download PDF

97. Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features

Author

Coppola, Nicola, primary, Alessio, Loredana, additional, Gualdieri, Luciano, additional, Pisaturo, Mariantonietta, additional, Sagnelli, Caterina, additional, Minichini, Carmine, additional, Di Caprio, Giovanni, additional, Starace, Mario, additional, Onorato, Lorenzo, additional, Signoriello, Giuseppe, additional, Macera, Margherita, additional, Angelillo, Italo Francesco, additional, Pasquale, Giuseppe, additional, and Sagnelli, Evangelista, additional

Published
2017
Full Text
View/download PDF

99. Bidirectional Barbed Suture in Laparoscopic Myomectomy: Clinical Features

Author

Ardovino M, Castaldi M. A, Fraternali F, Ardovino I, COLACURCI, Nicola, SIGNORIELLO, Giuseppe, COBELLIS, Luigi, Ardovino, M, Castaldi, M. A., Fraternali, F, Ardovino, I, Colacurci, Nicola, Signoriello, Giuseppe, and Cobellis, Luigi

Abstract

Objective: To compare bidirectional knotless barbed suture versus standard sutures, with either extracorporeal or intracorporeal knots, and to assess the feasibility, safety, and rapidity in repairing a uterine wall defect after laparoscopic myomectomy. Subjects and Methods: This was a randomized clinical study having a Canadian Task Force Classification of I. In tertiary-care university-based teaching hospitals, 117 women who underwent laparoscopic myomectomy were enrolled. In accord with randomization, uterine wall defects were closed with either extracorporeal (poliglecaprone 25; Monocryl (TM)-1; Ethicon Inc., Somerville, NJ) or intracorporeal (polyglactin 910; Vicryl (TM)-1; Ethicon Inc.) knots or a bidirectional knotless barbed suture (Quill (TM)-0; Angiotech Pharmaceuticals, Inc., Vancouver, BC, Canada). Results: Time required to suture was significantly lower in the group operated on with a bidirectional suture than in groups with traditional sutures (P

Published
2013

100. Long‐term improvement in cardiac magnetic resonance in β‐thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.

Author

Casale, Maddalena, Filosa, Aldo, Ragozzino, Alfonso, Amendola, Giovanni, Roberti, Domenico, Tartaglione, Immacolata, De Michele, Elisa, Cozzolino, Domenico, Rispoli, Giuliana, Palmieri, Francesco, Pugliese, Umberto, Scianguetta, Saverio, Signoriello, Giuseppe, Musallam, Khaled M., and Perrotta, Silverio

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results